Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit

 
• By Mandy Jackson

Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.

Diagnosis of Multiple Myeloma. Test tubes or bottles for blood, stethoscope and laboratory hematology analysis surrounded by text title of diagnosis of Multiple Myeloma lie in the doctor workplace

More from Market Snapshot

More from Scrip